Patient-reported outcomes (PROs) capture symptoms, functioning, quality of life, treatment burden and priorities directly from patients. Their integration into Molecular Tumor Board (MTB)-guided care remains limited and particularly challenging, as recommendations often involve off-label therapies, sparse evidence and...
L. Gräßel, S. Yacob, C. Strantz et al.· npj Precision Oncology· 0 citations
Immune checkpoint inhibitor (ICI) therapy has transformed melanoma treatment, yet many patients either fail to respond or develop resistance after an initial response. The cellular and spatial determinants within the tumor microenvironment (TME) that underlie these divergent ICI therapy outcomes remain poorly defined....
Sajib Chakraborty, E. Corrales, I. Godbole et al.· Genome Medicine· 0 citations
TAVR induces a coordinated thromboinflammatory response across systemic, cellular, and transcriptomic levels, characterized by systemic coagulation and inflammatory activation, platelet phenotypic alterations, and transcriptional enrichment of platelet activation pathways.
D. Hesselbarth, A. Hoelzle, S. Teegelbekkers et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.